Role of ganaton in antiemetic therapy. New treatment capacities

• 主要な著者: A. V. Snegovoy (著者), L. V. Manzyuk (著者)
• フォーマット: 図書
• 出版事項: ABV-press, 2014-08-01T00:00:00Z.
• 主題: article
• オンライン･アクセス: Connect to this object online.
• Notes: 1994-4098; 1999-8627; 10.17650/1994-4098-2010-0-4-49-53
• Keywords: antiemetics; nausea; vomiting; d2-antagonists; emetogenic complications; 5-ht3 and nk1-receptor antagonists; Gynecology and obstetrics; RG1-991
• Source: Опухоли женской репродуктивной системы, Vol 0, Iss 4, Pp 49-53 (2014)

The practical introduction of new effective drugs for the prevention and treatment of nausea and vomiting is one of the important constitu- ents of maintenance therapy in cancer patients, which helps maintain a good quality of life during drug treatment. This paper considers the main mechanisms of occurrence of nausea and vomiting and current recommendations for their prevention and gives the results of the authors' studies evaluating the use of ganaton, a D2-receptor antagonist, alone and in combination with 5-HT3-receptor antagonists for the prevention and treatment of acute and delayed nausea and vomiting. The drug has shown a high efficacy and it is recommended for clinical application.